Today: 20 May 2026
Coupang stock sinks nearly 10% as fresh data leak, U.S. subpoena rattle CPNG shares
5 February 2026
2 mins read

Coupang stock sinks nearly 10% as fresh data leak, U.S. subpoena rattle CPNG shares

New York, Feb 5, 2026, 14:04 EST — Regular session

  • Coupang shares slid roughly 9.7% in afternoon trading, hovering close to their lowest point of the day
  • Company says another 165,000 users were affected by the November leak but insists no payment or login details were compromised
  • The U.S. House panel has issued a subpoena to Coupang, while Bernstein initiates coverage with an Underperform rating.

Shares of Coupang Inc tumbled almost 10% Thursday, weighed down by a fresh cybersecurity alert from South Korea alongside a U.S. congressional subpoena deepening the company’s legal troubles. The stock fell 9.7% to $17.57 by 2:04 p.m. EST, sliding to as low as $17.53.

Timing is critical. Coupang’s Korean operations have been under a microscope ever since last year’s breach sparked political backlash in Seoul, complicating matters for U.S. investors eager for details on potential costs, penalties, and the company’s next steps.

Coupang revealed Thursday that data for another 165,000 users was exposed in the same breach reported last November. The leaked information includes names, phone numbers, and addresses, but payment details and login credentials were not affected. The company said users have been alerted following government protocols. This latest breach comes after a massive leak last year that hit over 33 million customers. A South Korean presidential adviser warned the incident is straining relations with Washington.

In Washington, the House Judiciary Committee subpoenaed Coupang amid its investigation into alleged discrimination against U.S. companies. The committee demands communications between Coupang and the South Korean government and has requested the company’s testimony. Coupang responded with a statement saying it will “fully cooperate,” including providing documents and witness testimony. Reuters

Bernstein jumped in with an Underperform rating on Coupang, setting a $17 price target, The Fly reported. On Wall Street, Underperform means the stock is forecasted to trail its peers over the long haul.

The selloff underscores how fast cybersecurity news can hit valuations. For a consumer platform, the threat extends beyond just remediation costs—it includes prolonged churn, increased scrutiny, and sluggish decision-making as investigations drag on.

Law firms ramped up public notices linked to the data breach fallout. Levi & Korsinsky issued a release highlighting a Feb. 17 deadline to file as lead plaintiff in a securities lawsuit, accusing the company of poor cybersecurity controls and delayed disclosure. (A lead plaintiff is the investor the court appoints to represent the entire class.)

Coupang confirmed the latest leak didn’t involve payment details or login credentials. That cuts down the immediate risk of fraud, though it doesn’t clear up the wider questions about ongoing investigations and possible fines.

If investigators determine the leak is contained and regulators hold back on penalties, the shares might find some relief. But if the situation worsens, expect more disclosures, stricter enforcement in South Korea, and growing litigation in the U.S., keeping the stock stuck under a shadow of negative headlines.

Traders have their eyes on South Korea as police prepare to summon Coupang Korea’s acting head, Harold Rogers, on Feb. 6 for questioning over alleged perjury tied to a National Assembly hearing, according to local media. Meanwhile, any move from the U.S. House panel on scheduling testimony or document requests could come swiftly.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Dow Jones today: Index slides about 1% as Alphabet capex plan stirs fresh AI jitters
Previous Story

Dow Jones today: Index slides about 1% as Alphabet capex plan stirs fresh AI jitters

Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next
Next Story

Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next

Go toTop